Key result
M-TEER trends toward fewer CV events and improves quality of life scores vs medical therapy across baseline tertiles.
Why the study?
It was unknown whether the effects of M-TEER on clinical outcomes vary by baseline health status as measured by the KCCQ, and what impact M-TEER has on post-randomization health status.
Does mitral transcatheter edge-to-edge repair improve clinical outcomes and health status compared to medical therapy alone in patients with symptomatic heart failure and moderate-to-severe ventricular secondary mitral regurgitation across different baseline health status levels?
RCT (n=505)
Does mitral transcatheter edge-to-edge repair improve clinical outcomes and health status compared to medical therapy alone in patients with symptomatic heart failure and moderate-to-severe ventricular secondary mitral regurgitation across different baseline health status levels?
M-TEER improves health status and consistently reduces the risk of heart failure hospitalization or cardiovascular death regardless of baseline health status in patients with heart failure and moderate-to-severe secondary mitral regurgitation.
Answers are grounded in this paper and cite their sources.
Supports M-TEER across baseline health status in HF with SMR; extends prior RCTs by confirming consistent trends and KCCQ gains.
BACKGROUND AND AIMS: Mitral transcatheter edge-to-edge repair (M-TEER) using the MitraClip device improves clinical outcomes in patients with moderate-to-severe ventricular secondary mitral regurgitation (vSMR) and heart failure (HF). This study evaluated whether the effects of M-TEER on clinical outcomes vary by baseline health status, as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ), and assessed the impact of M-TEER on health status post-randomization. METHODS: The RESHAPE-HF2 trial included patients with symptomatic HF and moderate-to-severe vSMR (mean effective regurgitant orifice area .25 cm2; 14% >.40 cm2, 23% <.20 cm2). The impact of baseline KCCQ-clinical summary score (CSS) on the effect of M-TEER on clinical outcomes was assessed using Cox proportional hazards models. Changes post-randomization in health status and responder analyses were performed to assess the odds ratio (OR) of improvement and deterioration in KCCQ scores. RESULTS: Among 505 patients, M-TEER reduced cardiovascular death or HF hospitalization risk [hazard ratio (HR): .71 (.48-1.05), .50 (.29-.85), and .73 (.38-1.41)] across KCCQ-CSS tertiles of <38.9, 38.9-66.1, and >66.1, respectively (P-trend = .53). Similar results were seen for total HF hospitalization (P-trend = .48). M-TEER improved KCCQ-CSS, total symptom score, and overall summary score at 1, 6, 12, and 24 months compared to medical therapy alone (P < .05 at all time points). More patients in the M-TEER arm experienced a ≥5-point [OR 3.38 (2.09-5.45)], ≥10-point [OR 3.12 (1.93-5.02)], and ≥15-point [OR 3.25 (1.94-5.45)] improvement, and less patients had a ≥5-point deterioration [OR .34 (.19-.57)] in KCCQ-CSS at 6 months. Similar results were seen across other KCCQ domains and all time points. CONCLUSIONS: In patients with HF and moderate-to-severe vSMR, M-TEER showed a consistent trend towards a lower risk of HF hospitalization, with or without cardiovascular death, across all KCCQ-CSS tertiles and improved health status over time.
No takes yet. Share an insight, caveat, or question.
Butler et al. (2025) conducted an RCT in Heart failure and moderate-to-severe ventricular secondary mitral regurgitation (n=505). Mitral transcatheter edge-to-edge repair (M-TEER) vs. Medical therapy alone was evaluated on Cardiovascular death or heart failure hospitalization (HR 0.71, 0.50, and 0.73, 95% CI 0.48-1.05, 0.29-0.85, 0.38-1.41, p=0.53). M-TEER showed a consistent trend towards lower risk of CV death or HF hospitalization across baseline health status tertiles and improved quality of life scores.
Synapse has enriched 10 related papers. Consider them for comparative context: